ICON's Nuloy Coronary Stent System receives CE Mark

Medical device company ICON Interventional Systems®, Inc. today announced it has received the CE Mark for the Nuloy Coronary Stent System, a next generation coronary stent made from a proprietary Molybdenum and Rhenium (MoRe®) alloy.  The MoRe material is 99.9% pure and Nickel free with superior strength and density as compared to standard stent materials such as Cobalt Chromium and Stainless Steel.  MoRe allows the fabrication of a stent platform which has extremely thin struts, superior flexibility, improved deliverability and lower profile, while not compromising radial strength or visibility.

David Kandzari, MD of the Piedmont Heart Institute in Atlanta, who has participated in the pre-clinical studies of stent deliverability offers, "My experience in the development and testing of this important new stent platform leads me to believe that it will offer the potential of a new standard in deliverability, due to the extremely thin struts, flexibility and low profile.  Importantly, the stent has radiographic visibility and radial strength equivalent to much bulkier devices."

The new material allows a stent with strut thickness of 63 microns, a reduction of more than 20 percent versus the leading stents in use today.  Dr. Antonio Colombo of Milan, Italy comments, "I have reviewed this new device and look forward to using it clinically, as it may offer a very strong advantage in enhanced visibility.  In addition, the thin struts and excellent deliverability should lead to very favorable BMS clinical results." 


ICON Interventional Systems


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New studies underscore the importance of inclusive approaches in peripheral artery disease treatment